Eli Lilly & Co. (LLY)

85.92
NYSE : Health Technology
Prev Close 86.07
Day Low/High 85.81 / 86.40
52 Wk Low/High 73.69 / 89.09
Avg Volume 3.79M
Exchange NYSE
Shares Outstanding 1.09B
Market Cap 93.42B
EPS -0.20
P/E Ratio N/A
Div & Yield 2.25 (2.51%)

Latest News

New Data Presented At The American Diabetes Association 78th Scientific Sessions® Reinforce Potential Of Lilly's Ultra Rapid Lispro In People With Type 1 And Type 2 Diabetes

New Data Presented At The American Diabetes Association 78th Scientific Sessions® Reinforce Potential Of Lilly's Ultra Rapid Lispro In People With Type 1 And Type 2 Diabetes

INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b...

Investigational Doses Of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise In Delivering Powerful Efficacy In People With Type 2 Diabetes

Investigational Doses Of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise In Delivering Powerful Efficacy In People With Type 2 Diabetes

Data from a Phase 2 trial will be presented for the first time at the ADA's 78th Scientific Sessions®

Weekly Roundup

Markets had a tumultuous week starting with increased trade war fears and ending with a modest oil production increase from OPEC.

U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit

U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit

INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.

U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit

U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit

INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.

Lilly Completes Acquisition Of ARMO BioSciences

Lilly Completes Acquisition Of ARMO BioSciences

INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc.

Novo Nordisk Stock Rises 4% Over 2 Sessions

Novo Nordisk Stock Rises 4% Over 2 Sessions

Pharma firm's new diabetes drug showed positive test results.

Lilly Declares Third-Quarter 2018 Dividend

Lilly Declares Third-Quarter 2018 Dividend

INDIANAPOLIS, June 18, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2018 of $0.

Weekly Roundup

Rate hikes and trade wars weighed on stocks this week.

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.

Jim's Daily Rundown

Jim discusses news on Qualcomm-NXP Semiconductors, why we would sell Constellation today, and mentions Raytheon, Eli Lilly, PepsiCo, Honeywell and Emerson Electric!

Latest Reasons to Avoid Alzheimer's Plays

Latest Reasons to Avoid Alzheimer's Plays

Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

The biopharmaceutical companies saw their stocks drop amid fallout of failed Alzheimer's drug trials.

Stocks Mixed After Trump-Kim Summit, Wall Street Looks to Fed Meeting

Stocks Mixed After Trump-Kim Summit, Wall Street Looks to Fed Meeting

Stocks finished mixed on Tuesday, following the summit between Donald Trump and North Korean leader Kim Jong Un and as Wall Street turns its attention the start of the Federal Reserve's two-day meeting.

Jim's Daily Rundown

Jim discusses our Salesforce buy, Eli Lilly, UnitedHealth and Cimarex and also answers a club member's question!

Peace Hopes Weigh on Defense Stocks

Shares of defense stocks slide after Trump meets Kim.

Trump Meets Kim, AT&T and Time Warner, McDonald's - 5 Things You Must Know

Trump Meets Kim, AT&T and Time Warner, McDonald's - 5 Things You Must Know

U.S. stock futures trade lower after a signed agreement between Donald Trump and North Korean leader Kim Jong Un offers few specifics on denuclearization of the Korean peninsula; a ruling on the AT&T and Time Warner merger is expected Tuesday; McDonald's reportedly to detail its restructuring plan.

Update On Phase 3 Clinical Trials Of Lanabecestat For Alzheimer's Disease

Update On Phase 3 Clinical Trials Of Lanabecestat For Alzheimer's Disease

Independent data monitoring committee advises lanabecestat is unlikely to meet primary endpoints, leading to decision to discontinue these trials

Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.

Jim's Daily Rundown

Jim discusses a Cimarex upgrade, Eli Lilly receiving positive attention, Microsoft and gaming, Facebook, and answers a club member's question on PepsiCo!

Elanco Animal Health Introduces New Respiratory PRRS Vaccine

Elanco Animal Health Introduces New Respiratory PRRS Vaccine

Manufacturer gives swine producers a new tool to combat the devastating disease

Lilly To Unveil New Data At The Annual European Congress Of Rheumatology, Furthering Commitment To Scientific Discovery In Immunology

Lilly To Unveil New Data At The Annual European Congress Of Rheumatology, Furthering Commitment To Scientific Discovery In Immunology

Highlights include new Phase 2 data for baricitinib in systemic lupus erythematosus

Weekly Roundup

Markets bathed in the afterglow of the strong jobs report for most of the week.

Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer By TRC Capital Corp.

Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer By TRC Capital Corp.

INDIANAPOLIS, June 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has learned of an unsolicited mini-tender offer by TRC Capital Corp.

Jim's Daily Rundown

Jim discusses Constellation Brands, Goldman Sachs and a new position in Salesforce.com.

DDW 2018: Patients With Moderate-to-Severe Ulcerative Colitis Achieved Clinical And Endoscopic Remission With Mirikizumab In Phase 2 Trial

DDW 2018: Patients With Moderate-to-Severe Ulcerative Colitis Achieved Clinical And Endoscopic Remission With Mirikizumab In Phase 2 Trial

- New data are the first safety and efficacy data for an IL-23p19 monoclonal antibody for the treatment of moderate-to-severe ulcerative colitis -

Trimming Eli Lilly

We'll book a small profit off recent strength as we rebuild our cash position.

TheStreet Quant Rating: C+ (Hold)